-+ 0.00%
-+ 0.00%
-+ 0.00%

Sanofi Says FDA Issues Complete Response Letter For Tolebrutinib In Non-Relapsing Secondary Progressive Multiple Sclerosis, Drug Remains Under Review In EU And Other Markets

Benzinga·12/24/2025 07:19:45
Listen to the news

Financial considerations

As communicated on December 15, 2025, Sanofi is conducting an impairment test in accordance with IFRS (IAS 36) on the intangible asset value attached to tolebrutinib with a status to be provided with Q4 and FY 2025 results in January 2026. The outcome of this test will have no impact to the business net income / business EPS and there is no change to the financial guidance for 2025.